Samuel Obeng

Dr. Samuel Obeng

Department of Pharmaceutical, Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SOSamuel Obeng
Samuel Obeng
SKShyam Kamble
Shyam Kamble
MRMorgan Elizabeth Reeves
Morgan Elizabeth Reeves
LRLuis F. Restrepo
Luis F. Restrepo
APAvi Patel
Avi Patel
CMChristopher R. McCurdy
Christopher R. McCurdy

1 September 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Juan Francisco LeonJuan Francisco Leon
Juan Francisco Leon
SOSamuel Obeng
Samuel Obeng
Marco MottinelliMarco Mottinelli
Marco Mottinelli
YCYiming Chen
Yiming Chen
TKTamara I. King
Tamara I. King
CMChristopher R. McCurdy
Christopher R. McCurdy

6 May 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SOSamuel Obeng
Samuel Obeng
THTakato Hiranita
Takato Hiranita
Juan Francisco LeonJuan Francisco Leon
Juan Francisco Leon
LMLance R. McMahon
Lance R. McMahon
CMChristopher R. McCurdy
Christopher R. McCurdy

10 December 2021 in Structure
Verified
Journal Article
Closed access
SWShushu Wei
Shushu Wei
NTNaveen Thakur
Naveen Thakur
ARArka Prabha Ray
Arka Prabha Ray
BJBeining Jin
Beining Jin
SOSamuel Obeng
Samuel Obeng
Rajan LamichhaneRajan Lamichhane
Rajan Lamichhane

29 August 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SOSamuel Obeng
Samuel Obeng
HWHuiqun Wang
Huiqun Wang
AJAbdulmajeed Jali
Abdulmajeed Jali
DSDavid L. Stevens
David L. Stevens
HAHamid I. Akbarali
Hamid I. Akbarali
YZYan Zhang
Yan Zhang

1 June 2016 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
JSJustin N. Siemian
Justin N. Siemian
SOSamuel Obeng
Samuel Obeng
YZYan Zhang
Yan Zhang
YZYanan Zhang
Yanan Zhang
JLJun-Xu Li
Jun-Xu Li
Although μ-opioids have been reported to interact favorably with imidazoline I2 receptor (I2R) ligands in animal models of chronic pain, the dependence on the μ-opioid receptor ligand efficacy on these interactions had not been previously investigated. This study systematically examined the interactions between the selective I2 receptor ligand 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) and three μ-opioid receptor ligands of varying efficacies: fentanyl (high efficacy), buprenorphine (medium-low efficacy), and 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-[(3′-isoquinolyl) acetamido] morphine (NAQ; very low efficacy). The von Frey test of mechanical nociception and Hargreaves test of thermal nociception were used to examine the antihyperalgesic effects of drug combinations in complete Freund’s adjuvant–induced inflammatory pain in rats. Food-reinforced schedule-controlled responding was used to examine the rate-suppressing effects of each drug combination. Dose-addition and isobolographical analyses were used to characterize the nature of drug-drug interactions in each assay. 2-BFI and fentanyl fully reversed both mechanical and thermal nociception, whereas buprenorphine significantly reversed thermal but only slightly reversed mechanical nociception. NAQ was ineffective in both nociception assays. When studied in combination with fentanyl, NAQ acted as a competitive antagonist (apparent pA2 value: 6.19). 2-BFI/fentanyl mixtures produced additive to infra-additive analgesic interactions, 2-BFI/buprenorphine mixtures produced supra-additive to infra-additive interactions, and 2-BFI/NAQ mixtures produced supra-additive to additive interactions in the nociception assays. The effects of all combinations on schedule-controlled responding were generally additive. Results consistent with these were found in experiments using female rats. These findings indicate that lower-efficacy μ-opioid receptor agonists may interact more favorably with I2R ligands than high-efficacy μ-opioid receptor agonists.